Last reviewed · How we verify
NCT05586048: AUGUST-AHF
Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure
trial testing Yiqi Fumai Lyophilized Injection(YQFM) in Acute Heart Failure in 1,200 participants. Status unknown.
30 November 2025
Quick facts
| Lead sponsor | China Academy of Chinese Medical Sciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,200 |
| Start date | 1 April 2023 |
| Primary completion | 30 November 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Yiqi Fumai Lyophilized Injection(YQFM) — full drug profile →
Conditions studied
- Acute Heart Failure — all drugs for Acute Heart Failure →
- Complementary Medicine — all drugs for Complementary Medicine →
- Chinese Medicine — all drugs for Chinese Medicine →
Sponsor
China Academy of Chinese Medical Sciences — full company profile →
Who can join
18 and older, any sex, with Acute Heart Failure or Complementary Medicine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this cohort study is to observe the effectiveness of Yiqi Fumai Lyophilized Injection (YQFM) in patients with acute heart failure (AHF). It mainly aims to assess the effectiveness of YQFM on the 90-day mortality or readmission rate in patients with AHF and compare the results with AUGUST-AHF RCT study. There will be no intervention, but information will be collected during the hospital stay and during the follow-up period of 180 days . Researchers will compare exposed group(patients who received YQFM) and non-exposed group(patients who didn't received YQFM) to see if there is difference on the 90-day mortality or readmission rate.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness of Yiqi Fumai lyophilized injection for acute heart failure: Rationale and design of the AUGUST-AHF cohort study.
Zhang X, Kang J, Zhang J, Chen Y, et al · · 2022 · cited 2× · PMID 36704479 · DOI 10.3389/fcvm.2022.1074406
Verify or expand the search:
- PubMed search for NCT05586048
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Heart Failure
Currently open trials in the same condition.
- NCT06587854 — a PRagmatic Observational Study of Congestion proFILes in patiEnts With Acute Heart Failure · recruiting
- NCT07008365 — The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure · Phase 3 · recruiting
- NCT06465498 — Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography · NA · recruiting
- NCT06597331 — Cardiac Assessment and Takotsubo-stunning Among COPD-exacerbations In-Hospital · recruiting
- NCT06166654 — Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload · Phase 4 · recruiting
Other China Academy of Chinese Medical Sciences trials
Trials by the same sponsor.
- NCT07319338 — Objective Vascular Biomarkers as Triage for Depression in Chronic Atrophic Gastritis · not yet recruiting
- NCT06874738 — A Real-world Clinical Study on the Treatment of Menopausal Syndrome With Liuwei Dihuang Pills · not yet recruiting
- NCT05138965 — the Method of Cotton Padding Promoting the Rectovaginal Fistula Surgery · completed
- NCT04932395 — Anshen Buxin Liuwei Pills for the Treatment of Cardiac Neurosis · Phase 4 · unknown
- NCT04714489 — Public Title：A Study on the Registration of The Use of Feilike HeJi in Adults · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05586048 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China Academy of Chinese Medical Sciences
- Last refreshed: 10 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05586048.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing